Results - Use of ffDNA to determine the fetal blood group and guide anti-D
The following papers have been published following this work,
please click on the links below to find out more:
Paper 1. Finning KM, Martin
PG, Soothill PW, Avent ND. Prediction of
fetal D status from maternal plasma: introduction of a new
noninvasive fetal RHD genotyping service. Transfusion. 2002
Aug;42(8):1079-85.
Paper 2: Daniels
G, Finning K, Martin P, Soothill P. Fetal blood
group genotyping from DNA from maternal plasma: an important
advance in the management and prevention of haemolytic disease of
the fetus and newborn. Vox Sang. 2004 Nov;87(4):225-32.
Paper 3: Chitty
LS, Finning K, Wade A, Soothill P, Martin B,
Oxenford K, Daniels G, Massey E. Diagnostic
accuracy of routine antenatal determination of fetal RHD status
across gestation: population based cohort study. BMJ. 2014 Sep
4;349:g5243. doi: 10.1136/bmj.g5243.
Paper 4:
Soothill P, Finning K, Latham T, Wreford-Bush T,
Ford J, Daniels G. Use of cffDNA to
avoid administration of anti-D to pregnant women when the fetus is
RhD-negative: implementation in the NHS. BJOG. 2014 Aug 21.
doi: 10.1111/1471-0528.13055.
